Form 8-K · Current report
Revvity 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000031791
- Accession no.
- 0000031791-26-000022
Summary
Revvity reported second-quarter 2026 revenue of $730 million and GAAP EPS from continuing operations of $0.48, with adjusted EPS of $1.41, and entered a definitive agreement signed July 31, 2026 to divest substantially all of its China Immunodiagnostics business for up to $200 million, a deal management believes is probable to close by the end of 2027. The company raised its full-year 2026 guidance on a pro forma basis to revenue of $2.83–$2.86 billion and adjusted EPS of $5.30–$5.40.
Key points
- Second-quarter 2026 revenue was $730 million versus $720 million a year earlier; pro forma revenue was $711 million, up 4% with 3% pro forma organic growth.
- Diagnostics segment revenue rose to $371 million from $354 million, while Life Sciences revenue fell to $359 million from $366 million.
- The China Immunodiagnostics divestiture represented approximately 6% of the company's total revenue in fiscal year 2025.
- CEO Prahlad Singh said results exceeded expectations and that a portion of recently received tariff refunds would fund increased investment.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition On August 4, 2026, Revvity, Inc. (the “Company”) announced its financial results for the second quarter ended July 5, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.